Shilajit and Blood Pressure After Menopause. What the Studies Actually Show.

Quick answer: There is no human trial showing shilajit lowers blood pressure as its primary finding. What the research does show is something worth understanding: shilajit improves the vascular mechanisms that sit underneath blood pressure. Oxidative stress markers fall. Arterial stiffness improves. Endothelial function improves. Nitric oxide rises substantially. These are the deeper mechanisms of vascular aging after menopause, and the research shows real movement in the right direction. This article covers what the studies actually measured, what they found, and where the honest ceiling of the evidence is.

Why the frame matters before looking at the data

When women come to this question, they're usually asking because blood pressure has crept up since menopause and they want to know whether shilajit is going to address it.

That's a fair question, and it deserves a direct answer.

Shilajit is not a blood pressure treatment. No trial has demonstrated it as a substitute for addressing blood pressure through other means. We're going to be clear about that throughout this article.

What the studies do show is that shilajit is working on the vascular machinery that underlies the pressure reading. Arterial stiffness. Endothelial function. Oxidative accumulation on the vessel wall. Nitric oxide availability. These are not incidental findings. They are the mechanisms of vascular aging after menopause, and they are exactly what the blood pressure reading reflects.

Whether improving those mechanisms changes the number on the cuff meaningfully for any individual woman is something the current evidence can't confirm. But the mechanisms themselves are worth understanding, because they matter for cardiovascular health beyond whatever happens to a single number.

The estrogen connection to arterial aging

Here is what happens to blood vessels after menopause, because this is the context the research is set against.

Estrogen doesn't only act on reproductive tissue. It acts on the lining of blood vessels, the endothelium, where one of its jobs is to support the production of nitric oxide. Nitric oxide is the signal that keeps blood vessels flexible and responsive. When your arteries need to relax and expand to handle blood flow, nitric oxide is what tells them to do it.

When estrogen signaling falls at menopause, nitric oxide production drops with it. Arteries become less flexible. Arterial stiffness goes up. This is one of the recognized mechanisms behind the blood pressure rise that often appears in the years after menopause. It's not primarily a sodium problem and it's not a single-mineral deficiency. It's a signaling problem.

Oxidative stress also rises in the post-menopausal years. Free radicals accumulate on the endothelial lining and damage it. The vascular system ages more quickly in the window right after menopause than it did before.

This is the terrain shilajit and the fulvic acid in it have been studied against.

The randomized controlled trial in elderly hypertensives

The most direct piece of evidence in this area is a randomized controlled trial published in the International Journal of Pharmaceutical and Phytopharmacological Research. The trial studied purified shilajit in elderly adults with hypertension.

It was controlled and randomized, which matters. And it looked directly at three of the mechanisms most relevant to arterial aging. Oxidative stress markers were measured. Arterial stiffness, captured as pulse wave velocity, was measured. Endothelial function was measured.

The group taking shilajit showed improvements across all three. Oxidative stress markers fell. Pulse wave velocity improved. Endothelial function improved.

These are the mechanisms underneath blood pressure. A vessel that's less stiff and whose endothelium is functioning better is a vessel that can regulate pressure more effectively. The trial measured those mechanisms directly and found movement in the right direction.

The trial did not report a clinically significant reduction in blood pressure numbers as its primary outcome. We're telling you this clearly because it matters for how you interpret the finding. The vascular markers improved. The headline number on the cuff was not the primary thing the study was built to show.

That distinction is honest and it's worth making, because the mechanisms are still genuinely meaningful for long-term vascular health.

The nitric oxide finding from the bone trial

There's a second piece of evidence that comes from an unexpected direction.

The 2022 Pingali trial at Nizam's Institute of Medical Sciences was designed to study bone mineral density in postmenopausal women with osteopenia. It ran for 48 weeks and it is the best-designed shilajit trial in postmenopausal women to date.

Among the markers it measured was nitric oxide, because nitric oxide is involved in bone metabolism and the researchers included it in the broader panel.

What they found was that nitric oxide rose 50 to 60 percent in the women taking shilajit, while the placebo group showed no comparable change.

A 50 to 60 percent rise in nitric oxide from a daily supplement is not a trivial finding from a vascular standpoint. This is the same molecule that keeps arteries flexible. The trial wasn't designed to measure blood pressure or endothelial function in isolation, so no direct conclusions about those outcomes can be drawn from it. But the nitric oxide number points in the same direction as the hypertension trial's endothelial function finding. The two pieces of evidence are consistent with each other.

The lipid and inflammatory picture

Two additional studies round out the picture from the metabolic side of cardiovascular health.

A 12-week randomized controlled trial by Niranjan and colleagues enrolled 40 adults with type 2 diabetes and tested purified shilajit on a panel of cardiovascular markers. LDL cholesterol fell 13 percent. Total cholesterol fell 21 percent. Triglycerides fell 16 percent. HDL rose 14 percent. The inflammatory marker hsCRP fell. Oxidative damage as measured by MDA fell. Endothelial function improved.

This was a small trial in a diabetic population, published in a smaller Indian journal without a PubMed listing. Read it accordingly. But the direction across every marker was favorable, and the endothelial function finding echoes what the hypertension trial showed.

An earlier open-label study by Sharma and colleagues in healthy adults over 45 days found stable blood pressure and pulse throughout the study, with reduced total cholesterol and triglycerides and improved antioxidant status. This was not a randomized controlled trial, so the finding that blood pressure stayed stable rather than falling carries less weight than it would from a blinded design. But it adds to the consistent pattern: shilajit is improving the oxidative and lipid environment around the vascular system, and doing it without destabilizing blood pressure in either direction.

Where the honest ceiling is

Shilajit is not a blood pressure medication and isn't positioned as one.

The evidence shows improvement in vascular mechanisms: the oxidative damage that accumulates on vessel walls, the arterial stiffness that comes with losing the estrogen signal, the endothelial function that determines how well blood vessels respond, the nitric oxide availability that keeps them flexible, and the lipid environment that either protects or burdens the cardiovascular system over time.

Those are real and meaningful targets. The research behind them is genuine. And the ceiling is also genuine: no trial has shown a clinically significant blood pressure reduction as a primary outcome.

We're telling you both because that's the accurate picture.

Safety

Across every human clinical study ever done on shilajit, zero serious adverse events have been reported. The trials that included blood pressure and pulse monitoring found them stable throughout. No unexpected changes to blood safety labs appeared in any published study.

Purity matters specifically in this context, because the last thing you want near a population managing cardiovascular risk is a supplement with variable heavy metal content. Optimum shilajit comes from the Altai mountains, purified and independently third-party tested for heavy metals, mycotoxins, and Prop 65 compliance. We're a small, family-owned company out of Florida.

What this means for the woman whose numbers are climbing

If blood pressure has crept up since menopause, the standard approaches focus on sodium, exercise, and in some cases medication. Those have real evidence behind them.

What's often missing from that picture is the vascular aging mechanism driven by the loss of estrogen signaling. The arterial stiffness, the falling nitric oxide, the oxidative accumulation on the vessel wall. These aren't addressable with sodium restriction. They're addressable with something that works on the signaling and the oxidative environment.

That's what shilajit is studied for. Not a replacement for managing cardiovascular health through other means. An approach to the terrain underneath the reading.

The Optimum Shilajit Trifecta brings together purified shilajit from the Altai mountains with pearl powder and bamboo silica in a formula designed for women over 50. You can find it here: Optimum Shilajit Trifecta.

Frequently asked questions

Does shilajit lower blood pressure?

No human trial has demonstrated shilajit as a blood pressure treatment. What the research shows is improvement in the vascular mechanisms that underlie blood pressure. Oxidative stress markers fell, arterial stiffness improved, endothelial function improved, and nitric oxide rose substantially across the relevant studies. Whether those changes translate to meaningful blood pressure reduction in any individual is something the current evidence can't confirm.

Why does blood pressure rise after menopause?

When estrogen signaling drops at menopause, nitric oxide production falls and arterial stiffness increases. Nitric oxide is what keeps blood vessels flexible. Without it, arteries lose their ability to relax and expand, and pressure builds. This mechanism is separate from sodium intake and is the vascular aging pathway most standard advice doesn't address.

What studies have tested shilajit for vascular health?

A randomized controlled trial in IJPP tested purified shilajit in elderly people with hypertension and found improvements in oxidative stress markers, arterial stiffness, and endothelial function. The 2022 Pingali bone trial found nitric oxide rose 50 to 60 percent as a secondary finding. A 12-week RCT by Niranjan found LDL, total cholesterol, triglycerides, hsCRP, and MDA all fell alongside endothelial function improvements.

What is endothelial function and why does it matter?

The endothelium is the lining of your blood vessels. When it's healthy, it responds to demand by signaling the vessel to relax and expand. When it's impaired, vessels stay rigid. Endothelial function is one of the core mechanisms that arterial stiffness and blood pressure both reflect. Improving it matters for cardiovascular health whether or not a pressure reading changes immediately.

Is shilajit safe for someone managing blood pressure?

Across every human clinical study on shilajit, zero serious adverse events have been reported. Trials that monitored blood pressure and pulse throughout found them stable. Optimum shilajit is third-party tested, heavy metal free, and Prop 65 compliant.

References

1. IJPP. Effect of purified shilajit on oxidative stress, arterial stiffness and endothelial function in elderly with hypertension. RCT. https://ijpp.com/effect-of-purified-shilajit-asphaltum-punjabianum-on-oxidative-stress-arterial-stiffness-and-endothelial-function-in-elderly-with-hypertension-a-randomised-controlled-study/
2. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
3. Niranjan et al. Effect of purified shilajit on cardiovascular risk markers in type 2 diabetics. International Journal of Ayurvedic and Pharmaceutical Research. 2016. https://ijapr.in/index.php/ijapr/article/view/322
4. Sharma et al. Evaluation of the safety and efficacy of shilajit on blood parameters in healthy volunteers. Ancient Science of Life. 2003. https://pubmed.ncbi.nlm.nih.gov/22557121/